# Breaking New Ground With Endoxifen: Augmentation Strategies in OCD Management—A Case Series

## TL;DR

This paper explores using Endoxifen to help OCD patients who don't respond to standard treatments.

## Contribution

The novel use of Endoxifen as an augmentation strategy for treatment-resistant OCD is presented through a case series.

## Key findings

- Endoxifen was used as an augmenting agent in OCD patients with psychiatric comorbidities.
- Patients who did not respond to conventional treatments showed potential improvement with Endoxifen.
- The case series suggests Endoxifen may be a promising augmentation strategy for OCD.

## Abstract

Obsessive–compulsive (OC) disorder (OCD) is a common and potentially disabling illness with a waxing and waning course. OCD significantly disrupts the quality of life. Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacological treatments for OCD and benefit up to half of the patients. Augmentation with low-dose antipsychotics is an evidence-based second-line strategy. Psychotherapy, including cognitive behavior therapy (CBT), is used both as first and second-line treatment. A significant portion of patients, however, do not respond to conventional treatments. We present a case series on the use of Endoxifen as an augmenting agent in patients with OCD and multiple psychiatric comorbidities who did not respond well to conventional pharmacotherapy.